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Background: Multiple studies have examined the incidence of secondary primary 
malignancies (SPMs) in gastric cancer patients in Europe and Asia. This retrospective 
review was conducted to analyze risk of SPM in patients with gastric cancer diagnosed 
in the United States.
Methods: We included adult patients diagnosed with gastric cancer from the surveil-
lance, epidemiology, and end result (SEER) 13 database. We calculated the risk of 
SPMs in these patients using the multiple primary standardized incidence ratio session 
of SEER*stat software and performed subset analyses of SPM with regard to age, sex, 
radiotherapy used, and latency period.
results: Among 33,720 patients, 1838 (5.45%) developed 2019 SPMs with an observed/
expected (O/E) ratio of 1.11 [95% confidence interval (CI) = 1.06–1.16, p < 0.001] and 
an absolute excess risk of 18.16 per 10,000 population. The median time to first SPM 
from the time of diagnosis of gastric cancer was 46.9 months (range 6–239 months). 
Significant excess risk was observed for gastrointestinal malignancies [O/E ratio 1.71 
(CI = 1.59–1.84, p < 0.001)], thyroid [O/E ratio 2.00 (CI = 1.37–2.8, p < 0.001)], and 
pancreatic cancer [O/E ratio 1.60 (CI =  1.29–21.96, p <  0.001)]. Risk of secondary 
melanoma, breast cancer, and prostate cancer was lower than in the general population.
conclusion: The risk for SPMs is significantly increased in adults with gastric cancer 
compared to the general population.
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inTrODUcTiOn
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death 
worldwide. The highest incidences are found in Eastern Asia and Central and Eastern Europe (1). 
Although the incidence of gastric cancer has declined over the last half century, the prognosis 
remains poor (2).
The majority of patients in the United States (US) present with regional or distant metastases, 
with an overall 5-year survival rate of 28.3% (1). By contrast, most Japanese gastric cancer patients 
are diagnosed in early stages of the disease and have an overall 5-year relative survival rate of 
over 50% (3).
TaBle 1 | Demographics of patients.
number (%)/median (range)
Total number of patient with gastric cancer 33,720
Gender
Male 20,474 (60.72%)
Female 13,246 (%)
Race
White 22,451 (66.58%)
Black 3942 (11.69%)
Other 7327 (21.73%)
Total number of SPM 2019
Total number of patient with SPM 1838 (5.45% of study population)
Total number of patient with 1 SPM 1676 (4.97% of study population)
Gender
Male 1084 (64.68%)
Female 592 (35.32%)
Race
White 1126 (67.18%)
Black 210 (12.53%)
Other 340 (20.29%)
Total number of patient with 2 or more SPM 162
Gender
Male 115 (70.99%)
Female 47 (29.01%)
Race
White 112 (69.14%)
Black 22 (13.58%)
Other 28 (17.28%)
Age at the time of diagnosis of SPM 
(median)
74 years (24.3 years–104.5 years)
Latency to develop first SPM 3.91 years (6 months–19.91 years)
Follow-up time (median) 6.91 years (6 months–20.91 years)
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Geographic disparities exist in treatment modality as well 
(4). Surgery remains the only potentially curative option (5). 
Although multimodal treatment is the standard of care for bulky 
localized disease, adjuvant chemotherapy is typically employed 
in Asia, adjuvant chemoradiation in North America, and neo-
adjuvant chemotherapy in European and Australasian nations 
(4). Patients with advanced or recurrent disease typically receive 
systemic chemotherapy, as it provides a survival advantage over 
other treatments (6).
Gastric cancer survivors are at risk for secondary primary 
malignancies (SPMs). This long-term complication was first 
described by Warren and Gates in 1932 (7). Synchronous malig-
nancies are defined as occurring with 6 months of the primary 
diagnosis, whereas metachronous tumors occur more than 
6  months after the initial event. The risk of SPM is dependent 
on factors including patient age, cancer stage at diagnosis, and 
treatment modality (8).
The risk of SPM in gastric cancer patients in the US is unknown. 
Given the global variations in gastric cancer incidence, treatment, 
and survival, we evaluated the risk of SPMs in adult gastric cancer 
patients in the US to determine if geographic disparities are pre-
sent. In addition, increased awareness of SPMs will provide the 
framework for pilot intervention studies and the development of 
evidence-based guidelines for gastric cancer survivors.
MeThODOlOgY
about seer Database
These data represent 14% of the US population, including the 
geographical areas of Atlanta, Connecticut, Detroit, Hawaii, 
Iowa, Los Angeles, New Mexico, rural Georgia, San Francisco-
Oakland, San Jose-Monterey, Seattle (Puget Sound region), Utah, 
and Alaska Natives (1). Comprehensive cancer data, including 
primary tumor site, staging, patient demographics, treatment, 
and survival from hospitals and cancer treatment facilities, are 
subjected to rigorous quality control studies, resulting in a mature 
database, with 98% case completeness.
study Population
We selected adult patients aged 18 years or more, diagnosed with 
gastric cancer as first primary malignancy from January 1992 to 
December 2012. Patients were followed from diagnosis to the 
date of last known vital status, death, or the last point of data 
collection. We excluded cases diagnosed at autopsy and those lost 
to follow-up. Using the Warren and Gates criteria (7) as modified 
by the NCI (9), SPM was defined as metachronous malignancy 
developing 6 months or more after an index gastric carcinoma.
Data analysis
We used SEER*stat software, Version 8.2.1 April 8, 2015 to 
calculate the standardized incidence ratio (SIR), absolute excess 
risk (AER), and confidence interval (CI) for SPM in patients, as 
previously diagnosed with gastric cancer. We analyzed that the 
risks of SPM by latency period (6–23 versus 24 months or more) 
and exposure to radiotherapy were determined.
The SIR, which is also known as the relative risk, is a relative 
measure of the strength of association between two cancers. It 
is calculated by dividing the observed incidence of SPM by the 
expected incidence of SPM [observed/expected (O/E) ratio] in 
the general population. AER is an absolute measure of the clinical 
burden of additional cancer per 10,000 occurrences in the popu-
lation. It measures the actual number of excess events normalized 
to the number of person years observed [AER = (O − E) PY].
resUlTs
A total of 33,720 patients diagnosed with primary gastric cancer met 
the study criteria. Patient demographics are presented in Table 1. 
A total of 1838 patients (5.26%) developed 2019 SPMs with an 
O/E ratio of 1.11 (CI = 1.06–1.16, p < 0.001; AER 18.16) (Table 2). 
A total of 1676 patients developed 1 SPM, and 162 developed 2 
or more SPMs. The average age at diagnosis of SPM was 74 years 
(24–104  years). The median time from primary diagnosis to 
development of first SPM was 46.9 months (range 6–239 months). 
Significant excess risk was observed for gastrointestinal, biliary, 
pancreatic, and thyroid cancers. Significantly, decreased risk was 
observed for secondary melanoma, breast, and prostate cancer.
sPM and age
All patients had an increased risk of gastrointestinal second 
primary malignancies. On subgroup analysis, older patients had 
TaBle 2 | Total sPM.
Total
Person at risk = 33,720;  
Person year at risk = 107,690.38
N O/e Two  
tail p
confidence 
interval
excess 
risk
All sites 2019 1.11 <0.001 1.06–1.16 18.16
All sites excluding non-
melanoma skin
2011 1.11 <0.001 1.06–1.16 18.16
All solid tumors 1813 1.12 <0.001 1.07–1.18 18.54
Brain and other CNS tumor 12 0.74 0.349 0.38–1.29 −0.4
Head and neck 36 0.62 0.002 0.43–0.85 −2.07
Thyroid 33 2 <0.001 1.37–2.8 1.53
Lung and bronchus 299 1.09 0.153 0.97–1.22 2.26
Esophagus 51 2.41 <0.001 1.79–3.17 2.77
Stomach 217 4.51 <0.001 3.93–5.16 15.69
Small intestine 24 3.06 <0.001 1.96–4.55 1.5
Colon, rectum, and anus 254 1.15 0.03 1.01–1.3 3.11
Liver, gallbladder, and other 
biliary
69 1.3 0.04 1.01–1.65 1.48
Pancreas 92 1.6 <0.001 1.29–1.96 3.19
Breast 124 0.8 0.011 0.67–0.95 −2.89
Female genital system 64 1.07 0.615 0.82–1.37 0.4
Male genital system 300 0.79 <0.001 0.7–0.88 −7.41
Urinary system 182 1.11 0.173 0.95–1.28 1.68
Soft tissue including heart 10 1.05 0.964 0.5–1.93 0.04
Skin excluding basal and 
squamous
40 0.64 0.003 0.46–0.87 −2.09
Lymphoma 76 0.95 0.709 0.75–1.19 −0.37
Myeloma 27 0.97 0.97 0.64–1.41 −0.08
Acute lymphocytic leukemia 3 2.08 0.352 0.43–6.08 0.14
Chronic lymphocytic 
leukemia
15 0.73 0.261 0.41–1.21 −0.51
Acute myeloid leukemia 22 1.44 0.122 0.9–2.18 0.63
Chronic myeloid leukemia 11 1.71 0.126 0.85–3.06 0.42
Kaposi sarcoma 3 2.06 0.357 0.43–6.03 0.14
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a significantly higher risk of SPMs of the esophagus (O/E ratio of 
2.28, CI = 1.67–3.06, p < 0.0001; AER 3.15), stomach (O/E ratio of 
3.66, CI = 3.13–4.26, p < 0.0001; AER 15.11), small intestine (O/E 
ratio of 2.93, CI = 1.81–4.48, p < 0.0001; AER 1.72), thyroid (O/E 
ratio of 1.95, CI = 1.25–2.9, p < 0.005; AER 1.45), and pancreas 
(O/E ratio of 1.55, CI = 1.24–1.92, p < 0.001; AER 3.77). Younger 
patients were at increased risk of malignancies of lung and bron-
chus (O/E ratio of 2.05, CI = 1.36–2.96, p < 0.001; AER 5.24), 
esophagus (O/E ratio of 4.05, CI =  1.49–8.81, p <  0.001; AER 
1.65), stomach (O/E ratio of 20.56, CI = 15.26–27.11, p < 0.0001; 
AER 17.39), colon (O/E ratio of 2.91, CI = 2.09–3.95, p < 0.0001; 
AER 9.84), and urinary system (O/E ratio of 2.47, CI = 1.57–3.71, 
p < 0.001; AER 5).
sPM and latency
The median time from primary diagnosis to development of first 
SPM was 47 months (range 6–229 months). All solid tumors were 
significantly increased after 24 months of latency (O/E ratio of 
1.18, CI = 1.12–1.24, p < 0.001; AER 30.42). The risk of malignan-
cies of thyroid (O/E ratio of 3.17, CI = 1.77–5.22, p < 0.001; AER 
3.08), esophagus (O/E ratio of 2.52, CI = 1.44–4.09, p < 0.005; 
AER 2.89), and small intestine (O/E ratio of 4.03, CI = 1.84–7.64, 
p  <  0.005; AER 2.03) was significantly increased within 
6–23 months of the index diagnosis. The risk of malignancies of 
esophagus (O/E ratio of 2.36, CI = 1.64–3.28, p < 0.0001; AER 
2.71), stomach (O/E ratio of 5.34, CI = 4.59–6.17, p < 0.0001; 
AER 19.9), small intestine (O/E ratio of 2.67, CI = 1.49–4.4, 
p < 0.005; AER 1.26), hepatobiliary system (O/E ratio of 1.54, 
CI = 1.17–1.99, p < 0.005; AER 2.79), pancreas (O/E ratio of 
1.69, CI =  1.32–2.13, p <  0.0001; AER 3.84), and lung and 
bronchus (O/E ratio of 1.18, CI =  1.03–1.34, p <  0.05; AER 
4.69) was increased after 24  months of latency compared to 
the general population.
sPM and radiation exposure
Of the 1838 patients who developed SPM, 421 received radio-
therapy. The risk of SPM at all sites was significant in both groups. 
Among patients with no radiation exposure, the risk of SPMs of 
the thyroid (O/E ratio of 1.69, CI = 1.06–2.56, p < 0.05; AER 1.06), 
esophagus (O/E ratio of 2.1, CI = 1.46–2.92, p < 0.0001; AER 2.16), 
stomach (O/E ratio of 4.43, CI = 3.8–5.13, p < 0.0001; AER 16.04), 
small intestine (O/E ratio of 3.17, CI = 1.94–4.9, p < 0.0001; AER 
1.61), and pancreas (O/E ratio of 1.52, CI = 1.19–1.91, p < 0.005; 
AER 2.9) was significantly increased. Patients with exposure to 
radiation had increased the risk of thyroid (O/E ratio of 3.13, 
CI = 1.56–5.6, p < 0.005; AER 3.3), esophagus (O/E ratio of 3.57, 
CI = 2.04–5.8, p < 0.0001; AER 5.08), stomach (O/E ratio of 4.96, 
CI = 3.56–6.73, p < 0.0001; AER 14.44), large bowel (O/E ratio 
of 1.52, CI = 1.16–1.96, p < 0.005; AER 8.92), and pancreas (O/E 
ratio of 1.96, CI = 1.2–3.02, p < 0.01; AER 4.31).
DiscUssiOn
There are currently more than 13 million cancer survivors in the 
US, with a projected increase to 18 million by 2022 (10). Early 
diagnosis and development of new agents continue to improve 
cancer outcomes. Long-term morbidity and premature mortality 
may occur in survivors, as a result of comorbidities, treatment, or 
disease-related factors.
In 2006, the Institute of Medicine report recommended 
the use of evidence-based guidelines to identify and manage 
the long-term effects of cancer, including surveillance for and 
prevention of recurrences and SPMs (11). Studies such as this 
not only increase awareness of secondary malignancies but also 
provide valuable information that may be used to pilot interven-
tions in care leading to improved outcomes for cancer survivors. 
SPMs are common in cancer patients with an overall cumulative 
incidence of 14% at 25 years of follow-up (12).
Previously published literature has examined the incidence 
of SPMs in gastric cancer patients in Asia, Europe, and the 
Middle East. This is the first study to examine the incidence 
of SPM in gastric cancer patients in the US. Previous studies 
are inconsistent regarding the risks for SPM in gastric cancer, 
but our results are in agreement with the literature that sug-
gests an increased risk for colon, liver, and pancreatic cancers 
TaBle 3 | second primary malignancies in gastric cancer.
reference number of 
patients
number of 
sPM
Odd’s ratio  
(95% ci)
Hiyama et al. (14) 61,168 1045 M: 0.84 (0.78–0.90)
F: 0.90 (0.79–1.01)
Lundegardh et al. (15) 34,506 962 1.16 (1.09–1.24)
Ikeda et al. (16) 2250 47 N/A
Bozzetti et al. (13) 105 10 N/A
Ikeda et al. (17) 1070 54 N/A
Current study 33,720 2019 1.11 (1.06–1.16)
N/A, not available; SPM, second primary malignancies; M, male; F, female;  
CI, confidence interval.
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(13–17). Many gastric cancer patients may receive radiotherapy, 
a known risk factor for secondary malignancies. A recent cohort 
study estimated the excess risk at 8% in patients surviving more 
than 1 year following treatment, resulting in 5 SPMs per 1000 
radiotherapy patients by year 15 after diagnosis (18). We have 
summarized rates of SPMs reported in the literature (Table 3). 
Our study is the largest study in the last 25 years. Contrary to 
the study by Hiyama et al., our study showed significant increase 
in risk of SPM in gastric cancer patients. Findings of our study 
will help us formulate evidence-based guidelines for follow-up 
of gastric cancer survivors.
The strengths of this study include its large sample size and 
long-term follow-up. The limitations of the study are related to 
the use of population-based registries. Surveillance, epidemi-
ology, and end result (SEER) database does not have comor-
bidities, lifestyle and risk factors, environmental exposure, and 
family history. SEER database does not have information on 
chemotherapy used. We were unable to analyze SPM by stage, 
because collaborative stage is not used for cases diagnosed prior 
to 2004 (19).
The risk of SPM is significantly increased in US patients with 
gastric cancer. The risk of any specific SPM is dependent on treat-
ment and time of latency. Evaluation for SPMs is critical in the 
follow-up of gastric cancer survivors.
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